X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (200) 200
agammaglobulinemia - chemically induced (141) 141
female (115) 115
male (107) 107
adult (75) 75
middle aged (69) 69
index medicus (49) 49
agammaglobulinemia - immunology (46) 46
child (39) 39
animals (37) 37
adolescent (33) 33
agammaglobulinemia (31) 31
aged (31) 31
agammaglobulinemia - complications (30) 30
immunology (28) 28
rituximab (28) 28
hypogammaglobulinemia (23) 23
arthritis, rheumatoid - drug therapy (21) 21
b-lymphocytes - immunology (20) 20
x-linked agammaglobulinemia (20) 20
child, preschool (19) 19
antineoplastic agents - adverse effects (18) 18
immunoglobulins (17) 17
infant (17) 17
agammaglobulinemia - drug therapy (16) 16
immunosuppressive agents - adverse effects (16) 16
treatment outcome (15) 15
agammaglobulinemia - blood (14) 14
immunoglobulin a - analysis (14) 14
immunoglobulin g - blood (14) 14
oncology (14) 14
agammaglobulinemia - etiology (13) 13
antibodies, monoclonal, murine-derived - adverse effects (13) 13
anticonvulsants - adverse effects (13) 13
hematology (13) 13
risk factors (13) 13
therapy (13) 13
immunoglobulin g (12) 12
immunoglobulin g - analysis (12) 12
time factors (12) 12
agammaglobulinemia - therapy (11) 11
carbamazepine - adverse effects (11) 11
prednisone - adverse effects (11) 11
research article (11) 11
young adult (11) 11
antibodies, monoclonal, murine-derived (10) 10
b-lymphocytes - drug effects (10) 10
care and treatment (10) 10
immunologic factors - adverse effects (10) 10
medicine, general & internal (10) 10
mice (10) 10
phenytoin - adverse effects (10) 10
research (10) 10
agammaglobulinemia - diagnosis (9) 9
allergy (9) 9
antibodies, monoclonal - adverse effects (9) 9
antibodies, monoclonal, murine-derived - therapeutic use (9) 9
chickens (9) 9
immunoglobulin m - analysis (9) 9
immunologic deficiency syndromes - chemically induced (9) 9
pediatrics (9) 9
protein-tyrosine kinases - antagonists & inhibitors (9) 9
protein-tyrosine kinases - metabolism (9) 9
retrospective studies (9) 9
rheumatoid-arthritis (9) 9
rheumatology (9) 9
rituximab - adverse effects (9) 9
allergy and immunology (8) 8
antigens (8) 8
autoimmune diseases (8) 8
carbamazepine (8) 8
clinical neurology (8) 8
cyclophosphamide - adverse effects (8) 8
drug therapy (8) 8
epilepsy - drug therapy (8) 8
follow-up studies (8) 8
gold - adverse effects (8) 8
immunization, passive (8) 8
immunoglobulins, intravenous - adverse effects (8) 8
immunoglobulins, intravenous - therapeutic use (8) 8
lymphopenia - chemically induced (8) 8
recurrence (8) 8
transplantation immunology (8) 8
aged, 80 and over (7) 7
antibody formation (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
bursa of fabricius - immunology (7) 7
disease (7) 7
gamma-globulins - adverse effects (7) 7
hemic and lymphatic diseases (7) 7
iga deficiency (7) 7
igg deficiency (7) 7
immune system diseases (7) 7
immunocompromised host (7) 7
immunodeficiency (7) 7
immunoglobulins - analysis (7) 7
immunoglobulins - blood (7) 7
immunoglobulins, intravenous - administration & dosage (7) 7
immunosuppression (7) 7
infection (7) 7
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (184) 184
German (13) 13
Japanese (8) 8
French (6) 6
Polish (4) 4
Spanish (4) 4
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Italian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 18, pp. 2493 - 2498
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, p. e0159607
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency... 
SURVIVAL | CLL | ACTIVATION | BRUTON TYROSINE KINASE | ONCOLOGY | MULTIDISCIPLINARY SCIENCES | IBRUTINIB | PCI-32765 | CHRONIC LYMPHOCYTIC-LEUKEMIA | GERMINAL CENTER | ANTIGEN | Lethargy - physiopathology | Protein-Tyrosine Kinases - metabolism | Diarrhea - physiopathology | Humans | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Weight Loss - drug effects | Diarrhea - chemically induced | Anorexia - physiopathology | Benzamides - administration & dosage | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Female | B-Lymphocytes - pathology | Drug Evaluation, Preclinical | Benzamides - adverse effects | Disease Models, Animal | Lymphoma, Large B-Cell, Diffuse - drug therapy | Drug Administration Schedule | Lymphoma, Large B-Cell, Diffuse - enzymology | Lethargy - chemically induced | Lymphoma, Large B-Cell, Diffuse - mortality | B-Lymphocytes - drug effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Vomiting - chemically induced | Animals | B-Lymphocytes - immunology | Agammaglobulinaemia Tyrosine Kinase | Dogs | Pyrazines - adverse effects | Cell Line, Tumor | Anorexia - chemically induced | Lymphoma, Large B-Cell, Diffuse - veterinary | Vomiting - physiopathology | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Care and treatment | Safety and security measures | Dosage and administration | Non-Hodgkin's lymphomas | Research | Antineoplastic agents | Cell proliferation | Cell culture | Flow cytometry | Veterinary colleges | Anorexia | Leukemia | Cytotoxicity | Malignancy | Kinases | Veterinary medicine | Vomiting | Quality | Inhibition | Protein-tyrosine kinase | Tyrosine | Internal medicine | Hematology | Agammaglobulinemia | Diarrhea | Gene expression | Lymphoma | Bruton's tyrosine kinase | Inhibitors | Lymphocytes B | Lethargy | Lymphomas | Cancer | B-cell lymphoma
Journal Article
Journal Article
Clinical Nephrology, ISSN 0301-0430, 2016, Volume 85, Issue 6, pp. 340 - 345
Rituximab (RTX) is regarded as a relatively safe and effective treatment for children with steroid-dependent nephrotic syndrome (SDNS). However, late-onset... 
Humans | Child, Preschool | Male | Nephrotic Syndrome - drug therapy | Young Adult | Agammaglobulinemia - chemically induced | Time Factors | Adolescent | Female | Immunosuppressive Agents - adverse effects | Prednisolone - therapeutic use | Retrospective Studies | Neutropenia - chemically induced | Child | Rituximab - adverse effects
Journal Article
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 05/2017, Volume 15, Issue 5, pp. 835 - 847
Summary Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple... 
ibrutinib | blood platelets | agammaglobulinemia | lymphoma | hemorrhage | CONTROLLED-TRIAL | THROMBUS FORMATION | X-LINKED AGAMMAGLOBULINEMIA | ATRIAL-FIBRILLATION | SINGLE-AGENT IBRUTINIB | BRUTONS TYROSINE KINASE | ACALABRUTINIB ACP-196 | B-CELL MALIGNANCIES | CHRONIC LYMPHOCYTIC-LEUKEMIA | PERIPHERAL VASCULAR DISEASE | PLATELET GLYCOPROTEIN-VI | HEMATOLOGY | Anticoagulants - administration & dosage | Risk Assessment | Pyrimidines - administration & dosage | Humans | Risk Factors | Hemorrhage - prevention & control | Protein Kinase Inhibitors - adverse effects | Anticoagulants - adverse effects | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Animals | Drug Interactions | Blood Coagulation - drug effects | Signal Transduction - drug effects | Antineoplastic Agents - adverse effects | Blood Platelets - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Pyrimidines - adverse effects | Hemorrhage - chemically induced | Blood Platelets - drug effects | Drug Substitution | Platelet Aggregation Inhibitors - adverse effects | Pyrazoles - adverse effects | Tyrosine | Anticoagulants | Aspirin | Antiinflammatory agents | Fish oils | Immunoproliferative diseases | Antagonists | Inflammation | Hemorrhage | Bruton's tyrosine kinase | Bleeding | Chemotherapy | Lymphocytes B | Vitamin E | Nonsteroidal anti-inflammatory drugs | Protein-tyrosine kinase | Vitamin K | Bruton type agammaglobulinemia | Lymphoma | Ibrutinib | Blood Platelets
Journal Article
Journal Article
Journal of Pediatric Hematology/Oncology, ISSN 1077-4114, 2017, Volume 39, Issue 1, pp. 1 - 5
Journal Article